Genprex receives Canadian patent allowance for REQORSA combo with PD-1/PD-L1 in lung cancer

Genprex, Inc.

Canadian IPO issued Notice of Allowance for patent covering REQORSA with PD-1/PD-L1 antibodies for NSCLC and SCLC.
Patent expands existing IP portfolio for Acclaim-3 trial evaluating REQORSA combinations.
Canadian Cancer Society estimates 32,900 new lung cancer cases in 2026; 19,300 deaths.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.